Gilead, AstraZeneca/Daiichi Sankyo present mid-stage data on rival TROP2 antibody-drug conjugates - Endpoints News
endpts.comSubmitted by endpointsnews6292 in business
Preliminary mid-stage data from two rival TROP2-targeting ADCs advanced by AstraZeneca/Daiichi Sankyo and Gilead, combined with immune checkpoint inhibitors, have provided a first glance at the risk-benefit balance of this approach in non-small cell lung canc…